Cowen and Company reissued their buy rating on shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) in a report published on Thursday. The firm currently has a $22.00 price target on the stock.

Several other equities research analysts also recently weighed in on the company. BTIG Research reissued a buy rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a buy rating to a hold rating in a report on Wednesday, May 3rd. ValuEngine raised Oxford Immunotec Global PLC from a sell rating to a hold rating in a report on Friday, June 2nd. Finally, Piper Jaffray Companies reissued a buy rating and issued a $26.00 price target on shares of Oxford Immunotec Global PLC in a report on Thursday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $21.00.

Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 18.12 on Thursday. The company’s 50-day moving average is $16.18 and its 200 day moving average is $14.93. Oxford Immunotec Global PLC has a 52-week low of $8.88 and a 52-week high of $19.51. The company’s market cap is $418.14 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, hitting the consensus estimate of ($0.32). The business had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The company’s quarterly revenue was up 35.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) earnings per share. Equities analysts forecast that Oxford Immunotec Global PLC will post ($1.07) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Cowen and Company Reaffirms “Buy” Rating for Oxford Immunotec Global PLC (NASDAQ:OXFD)” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/07/cowen-and-company-reaffirms-buy-rating-for-oxford-immunotec-global-plc-nasdaqoxfd.html.

In other Oxford Immunotec Global PLC news, VP Elizabeth M. Keiley sold 4,085 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $15.01, for a total value of $61,315.85. Following the completion of the sale, the vice president now owns 25,393 shares of the company’s stock, valued at $381,148.93. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $16.06, for a total value of $481,800.00. Following the completion of the transaction, the chief executive officer now owns 491,668 shares of the company’s stock, valued at $7,896,188.08. The disclosure for this sale can be found here. In the last three months, insiders sold 147,085 shares of company stock valued at $2,275,928. Corporate insiders own 7.58% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Redmile Group LLC boosted its position in shares of Oxford Immunotec Global PLC by 17.9% in the first quarter. Redmile Group LLC now owns 2,004,849 shares of the company’s stock valued at $31,055,000 after buying an additional 303,800 shares during the last quarter. AXA boosted its position in shares of Oxford Immunotec Global PLC by 52.5% in the first quarter. AXA now owns 917,468 shares of the company’s stock valued at $14,212,000 after buying an additional 315,718 shares during the last quarter. Grandeur Peak Global Advisors LLC boosted its position in shares of Oxford Immunotec Global PLC by 8.3% in the first quarter. Grandeur Peak Global Advisors LLC now owns 703,378 shares of the company’s stock valued at $10,895,000 after buying an additional 53,975 shares during the last quarter. Endurant Capital Management LP boosted its position in shares of Oxford Immunotec Global PLC by 3,456.1% in the first quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock valued at $8,844,000 after buying an additional 554,915 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Oxford Immunotec Global PLC by 97.8% in the first quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock valued at $5,628,000 after buying an additional 179,600 shares during the last quarter. Hedge funds and other institutional investors own 87.47% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.